Evidence map›Paper›PMID 41568144›Full record

ArticleiScience2026

Combined prostate cancer vaccine plus immune checkpoint inhibition synergizes to eliminate prostate cancer.

Gabriel Carreno-Galeano, Seema Dubey, Kenneth A Iczkowski, Peter Van Veldhuizen, Uzoma A Anele, Jamie C Messer, Murali K Ankem, Dev Karan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gabriel Carreno-GaleanoDepartment of Urology, Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.
Seema DubeyDepartment of Urology, Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.
Kenneth A IczkowskiDepartment of Pathology and Laboratory Medicine, University of California-Davis Health, Sacramento, CA 95817, USA.
Peter Van VeldhuizenDivision of Hematology and Oncology, University of Michigan Health-West, Wyoming, MI 49519, USA.
Uzoma A AneleDepartment of Urology, Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.
Jamie C MesserDepartment of Urology, Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.
Murali K AnkemDepartment of Urology, Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.
Dev KaranDepartment of Urology, Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.

Funding

Modulation of host intrinsic immunity to reduce prostate cancer disparityR01CA204786 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI KARAN, DEV · 2016 to 2021
$1.5M
Guadecitabine-directed immune regulation in targeting prostate cancerR21CA292333 · NCI · UNIVERSITY OF LOUISVILLE · PI Dev Karan · 2025 to 2026
$420k
NCI NIH HHS R01 CA204786NCI NIH HHS R21 CA292333
6 · The paper itself

Abstract

Immunotherapy has improved outcomes in many cancers, yet the clinical benefits remain limited in prostate cancer. We evaluated whether an adenovirus-based bivalent prostate cancer vaccine (Ad-PS2) targeting two tumor antigens could be strengthened by combination with immune checkpoint blockade. Using immunocompetent mouse models, we found that Ad-PS2 combined with low-dose anti-CTLA4 generated robust anti-tumor immunity capable of eliminating established tumors, exceeding the effects of either treatment alone. Tumor-free mice resisted subsequent tumor rechallenge, indicating durable immune protection. Tumor analysis revealed a significant increase in intratumor CD8

Indexed as

BiotechnologyCancerImmunology

Identifiers

PMID41568144
PMCPMC12818091

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.